Malaysia Q2 Economy Grows 5.8%, Beating Forecasts on Strong Tech Exports and Domestic Demand 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
PayPal Rejects $53 Billion Stripe-Advent Takeover Offer as Too Low: Report 
US Inflation Expected to Ease in June, but Fed Rate Hike Risks Persist Amid Middle East Tensions 
China Home Prices Fall Again in June Despite Slower Pace of Decline 
Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
Port of Los Angeles Posts Record June Cargo Volume as Importers Rush Ahead of U.S. Tariffs 
Gold Prices Head for Biggest Weekly Loss Since June as Fed Rate Outlook Weighs 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
US Stock Futures Fall as Netflix Outlook, Chip Selloff and Iran Tensions Weigh on Markets 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Dollar Slides as Softer US Inflation Dims Fed Rate Hike Expectations 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Asian Stocks Rally as Cooling U.S. Inflation Boosts Fed Rate Cut Hopes 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Hyundai Pharmaceutical revealed on Tuesday, July 6, that it has submitted an application so it can start selling its abortion pill in South Korea. The company filed for authorization to market at the Ministry of Food and Drug Safety.
Hyundai Pharm is intending to start selling its Mifegymiso that is composed of four tablets of misoprostol and one tablet of mifepristone. Mifepristone is being sold in Korea under the brand name Mifegyne.
First legal abortion pill in S. Korea
According to The Korea Herald, if the ministry will give a go signal for the sale of Mifegymiso, it would effectively become the very first abortion pill that will be legally marketed in the country. In 2019, the Constitutional Court reversed the ban on abortion in the first 14 weeks of pregnancy, so this paved the way for the pills to be produced.
Hyundai Pharm will be distributing Mifegymiso to the market as a prescription drug. This means that only patients with proper medical advice from health professionals will be able to obtain the drug. Without the supervision of a certified health advisor, an individual will not be allowed to purchase the abortion pill.
The U.S. Food and Drug Administration stated that abortion pills are safe to use in the first nine or 10 weeks of pregnancy. While it seems that more and more groups are supporting and even promoting abortion pills, it was reported that the National Assembly is working on revising the Pharmaceutical Affairs Act so it can bar the advertising of the drug.
The marketing license for Mifegymiso
Korea Biomedical Review reported that Hyundai Pharm’s filing for approval for the abortion drug has gained attention because the Ministry of Health and Welfare already granted repayment for doctor’s education and counseling sessions about medical abortion.
The policy asks doctors to give educational counseling to pregnant women regarding abortion. They are allowed to explain the procedures for abortion, including precautions before and after the surgery. The physicians will also be taught about the physical and mental complications of abortion and contraception.
Meanwhile, Hyundai Pharm stated it will do its best to gain approval. “We will closely work with the drug developer to accelerate the regulatory nod for the drug,” a company official said.
